The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'


BioCryst gets additional NIAID funding to develop BCX4430 for hemorrhagic virus diseases.....           Lilly's Trulicity type 2 diabetes drug gets FDA approval.....           Novo Nordisk's Phase IIIb trial of Ryzodeg fails to meet primary endpoint.....           Innovus Pharma inks distribution deal with Tramorgan for Sensum+ in UK.....           GSK to pay £297m fine over bribery scandal in China.....           GSK China scandal resolved with $500M fine and suspended jail sentence.....           Europe approves Gilead's cancer drug Zydelig amid challenging pricing environment.....           Inversion pushback won't scare Horizon Pharma out of Ireland move.....           President and advisory panel zero in on combating antibiotic resistance.....           Novo finds new way to sell Tresiba in EU while awaiting another shot in U.S......           Analysts: Bayer could use plastics proceeds to fund a deal for Zoetis.....           Boehringer, CureVac to develop next generation lung cancer immunotherapy.....           Navidea's Lymphoseek cancer drug gets FDA orphan drug status.....           Axxess Pharma to launch new all natural, fat burning, ready to drink (RTD), protein meal replacement within 15 days.....           biOasis begins MPS II trial with Lysosomal storage disease expert Dr. Maurizio Scarpa and The Brains for Brain Foundation.....           MYOS inks deal with HMT to conduct clinical metabolomic trial in subjects using fortetropin.....           Spectrum out-licenses rights for China to CASI Pharmaceuticals for three of its drugs.....           Bayer plans to focus entirely on Life Science businesses.....           Enumeral gets Phase II SBIR contract from NCI to advance human tissue immuno-oncology profiling.....           MJFF enters into new research collaboration with Bachmann-Strauss Dystonia and Parkinson Foundation.....           Achaogen enrolls first patient in Phase III trial of Plazomicin to treat infections caused by Carbapenem-Resistant Enterobacteriaceae.....           Prosensa starts re-dosing of drisapersen in North America in patients with Duchenne muscular dystrophy.....           Isis Pharma gets $4m milestone payment from Achaogen for Phase III plazomicin trial.....           Merck Serono, Sutro Biopharma ink deal for new antibody drug conjugates.....           Put a lid on 'Low-T' drug use, FDA panel advises, threatening AbbVie, Lilly meds.....           NICE says 'yes' to GSK's melanoma pill, but only with a price cut.....           Bayer brings $12.9B plastics spinoff to Big Pharma's slim-down party.....           Real-world hep C patients drop off pricey Sovaldi, CVS study finds.....           Glaxo Ebola vax shows no adverse effects so far in first human trial.....           FDA backs ED upstart Stendra as a fast-acting alternative to Viagra.....           Sun Pharma and Merck sign exclusive worldwide licensing agreement for Tildrakizumab.....           Sanofi, MyoKardia partner to develop new therapies for genetic heart disease.....           MGB Biopharma gets £4m to advance new lead antibacterial MGB-BP-3 into clinical development.....           Takeda reports positive Phase III trial results of trelagliptin succinate to treat type 2 diabetes.....           Soligenix secured FDA clearance of Phase III trial of lymphoma drug SGX301.....           MedGenesis, Pfizer partner on Parkinson's disease treatments.....           Endo offers $2.2bn to acquire Auxilium.....           US FDA approves Aurobindo?s generic anti-infective drug.....           GSK resolves risk management violation issue at Montana facility in US.....           FDA approves Movantik tablets for opioid-induced constipation treatment.....           Roche commences phase III clinical trials for lampalizumab.....           Akashi Therapeutics acquires global rights to GsMTx-4 compound.....           Lupin and Merck Serono enter into strategic alliance.....           Pension fund sues AbbVie over expected high taxes from Shire deal.....           Sanofi and MannKind hatch plan to boost the margins on Afrezza.....           Are obesity drugs nearing a breakout? Novo, Takeda think so.....           Regeneron nabs FDA 'breakthrough' tag for new Eylea use in diabetics.....           Endo CEO touts 'exciting' $2.2B bid for Auxilium, but his target may not agree.....           Can AstraZeneca turn its Movantik constipation pill into a blockbuster?.....           First-to-market launch? Bonus--but double bonus if you're Big Pharma.....           US beefs up efforts to fight Ebola.....           AstraZeneca, Lilly to develop and commercialize BACE inhibitor to treat Alzheimer?s disease.....           HYD Pharma successfully completes research phase of new cancer drug.....           Merck releases Phase III study data of oral treatment for osteoporosis.....           Sagent Pharmaceuticals launches Ketorolac Tromethamine Injection, USP.....           PTC Therapeutics Expands Global Presence in Support of Translarna? Launch in Duchenne Muscular Dystrophy.....           Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin.....           Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study.....           Cardiorentis announces €45m financing with HealthCare Royalty Partners.....           NY sues Actavis and Forest for 'monopoly' on Alzheimer's drug.....           Switzerland wants to slash drug prices? Not so fast, say Novartis and Roche.....           Allergan, Valeant agree on meeting date. Now, the fight for shareholder votes.....           UPDATED: With FDA confab looming, Chantix experts can't persuade court to unseal Pfizer records.....           New COO engineers a management shake-up at Takeda.....           Roche says fake MabThera has surfaced in EU.....           Mylan, Ranbaxy, others to bring cheap Sovaldi to 91 markets.....           Study: Roche's cheaper Avastin just as safe as Lucentis in eye disease.....           Balky payers, beware: Gilead eyes $95K-or-so price for Sovaldi combo pill.....           Salix hands off Relistor, other drugs to Lupin in Canada.....           Would Ian Read keep his AZ deal promises? U.K. panel eyes new rules to enforce them.....           Pfizer, Ranbaxy prevail in antitrust fight over Lipitor generics.....           Lakewood-Amedex gets notice of allowance from USPTO for new patent covering nanoRNA gene-silencing technology.....           Grafix randomized controlled clinical trial recognized as high quality DFU trial in recent wounds supplement.....           Marina Biotech announces continued worldwide expansion of Delivery Technology Intellectual Property Estate.....           Prosonix confirms potential of MCP Technology to develop new FDC therapies for respiratory diseases.....           NeoStem enters into license deal with Rockefeller University to expand cancer immunotherapy.....           FDA approves Takeda and Orexigen's Contrave for chronic weight management.....           Cellerant gets $47.5m contract to support development of CLT-008.....           Lilly says with new data, it will seek another approval for Cyramza next year.....           Novo and Orexigen obesity drugs are coming, but will consumers embrace them?.....           With inversion pushback mounting, Akorn eyes bid for UCB subsidiary.....           Amarin loses a second FDA appeal over omega-3 pill Vascepa.....           J&J trims pension benefits for new hires.....           As America's diabetes problem grows, so do prices on Lilly's Humulin.....           Lilly says with new data, it will seek second approval for Cyramza next year.....           Asterias, Cancer Research UK ink deal for new lung cancer vaccine.....           Genocea begins Phase IIa trial of GEN-004 to treat pneumococcus.....           FDA grants orphan drug status for Viamet's VT-1129 to treat cryptococcal meningitis.....           Abbvie reports positive Phase III trial results of Humira in hidradenitis suppurativa patients.....           Oxygen Biotherapeutics halts Phase IIb traumatic brain injury trial of Oxycyte.....           RSS NEWSFEED....
APS PharmSci 2014
Declared Huge Success
 
Please browse some of the messages below from the Conference Science Chair, APS Chair and Chief Scientist regarding their positive experiences at the recent APS PharmSci Conference.

READ MORE
Message from Linda Hakes-Conference Science Chair
It was a tremendous honour to be asked to be the Conference Science Chair for PharmSci 2014 but also more than a little daunting. The previous holders of the position had helped to establish the meeting as the premier UK conference on the pharmaceutical sciences and I didn’t want to let the side down.











READ MORE
Message from Bill Dawson, Chair APS
We had an excellent group of plenary speakers with topics ranging from patient engagement through a very personal view of GI absorption and uptake to cannabis and non-invasive detection of cardiac disease. Open innovation and partnership strategies were key to two of the plenaries and all the talks reflected the holistic nature of the pharmaceutical science discipline.











READ MORE
Message from Claire Thompson-APS Chief Scientist
The APS PharmSci conference was, once again, a huge success. Gathering more than 550 scientists from industry, academia and regulatory agencies, the conference showcased innovation in research, ranging from graphene to regenerative medicine and biopharmaceutics to theranostics.






Keep your eye open for more reports, photos, feedback from the conference to follow over the coming weeks.
 
Welcome to
The Academy of
Pharmaceutical Sciences
 
The Academy of Pharmaceutical Sciences is the professional body for the Pharmaceutical Sciences in United Kingdom. A Pharmaceutical Scientist is an individual who contributes to bringing a new drug from concept through to a medicinal product. This includes, but is not exclusive to, individuals in academia, industry, regulation, clinical research and manufacturing.

The mission of the Academy of Pharmaceutical Sciences is to champion innovation and opportunity in Pharmaceutical Sciences for the delivery of medicines.

In order to achieve this mission, our aims are to:

  • Promote the Pharmaceutical Sciences to stakeholders to facilitate understanding and achieve engagement
  • Share learning, drive collaboration, partnership and innovation
  • Deliver insights into industry and academic roles for aspiring scientists

Latest News
Unique leadership event for women in healthcare science leadership
TUESDAY, 16 SEPTEMBER 2014
The Academy of Pharmaceutical Sciences (APS) and Royal Pharmaceutical Society (RPS) are organising a symposium on the 7 October 2014 for women in healthcare science leadership.. The organisers have put together a panel of leading professionals to help women develop their careers and includes eminent speakers from across clinical pharmacy, academic research and industry. The event is attracting a wide audience of individuals involved in leadership in the healthcare science and we would love to see you there.. . Are you looking to take the next step in your career? Are you ready to set new challenges and enhance your leadership skills?. Join us to hear from inspiring leaders in academic research, clinical pharmacy, and industry.. Helen Gordon, Chief Executive, Royal Pharmaceutical Society, says: “Our Women in healthcare science leadership symposium is a new event, developed to support women in existing or aspiring leadership roles. Attending will provide you with the perfect opportunity to challenge what you know about yourself and develop practical skills that will support your career. I for one am looking forward to hearing from our great line-up of speakers, who I’m sure will inspire and motivate you to excel and lead others in your field.”. The symposium has great networking potential with speakers from across clinical pharmacy, academic research and life sciences including:. Cathy Mooney MRPharmS, Deputy Director of Quality and Safety, University College London Hospitals NHS Foundation Trust Harriet Fear, CEO, One Nucleus Helena Morrissey CBE, CEO, Newton and Founder 30% Club Philippa Roberts MRPharmS, Director of Pharmacy and Risk Management, Wirral University Teaching Hospital NHS Foundation Trust Themes include leadership, innovation and entrepreneurship. During the day, you will:. Learn how to develop your leadership skills and successfully drive your career forwards Identify the successes and challenges for women in the workplace Discuss real life experiences with leading healthcare practitioners Examine the benefits of diversity in the workplace Learn how to overcome the barriers (both real and perceived) to becoming a leader Learn how to influence at the most senior level and to build networks. There will also be a Q&A session, giving you the unique opportunity to ask specific questions relating to your career.. We aim to provide you with the skills and confidence to successfully drive your career forward. Don't miss out: view the full programme and register today.. http://www.rpharms.com/conferences/women-in-healthcare-science-leadership -symposium.asputm_medium=email&utm_source=Royal+Pharmaceutical+Society &utm_campaign=4695578_Women+in+healthcare+event+-+generic&dm_i=EQ,2S N4Q,G415KU,A5V2J,1.
Award Winners at APS PharmSci 2014
WEDNESDAY, 3 SEPTEMBER 2014
APS Invited lecture at PharmSci Conference 2014 on Monday September 8th from 13.45-14.35. . The APS are pleased to announce that Abdul Basit will deliver the APS lecture this year entitled Gut instincts: explorations in intestinal physiology and drug delivery. The APS lecture award is sponsored by AstraZeneca and is awarded to nominated members of APS who have made outstanding scientific contribution in their work and are ambassadors in their area with an international reputation.. Abdul Basit holds the position of Professor of Pharmaceutics at the University College London (UCL) School of Pharmacy. He is also a Visiting Professor in the Faculty of Chemical and Pharmaceutical Sciences at the University of Chile. Furthermore, he holds an Honorary Research Fellow in Gastroenterology at the Wingate Institute of Neurogastroenterology, Queen Mary College, University of London.. Abdul's research sits at the interface between pharmaceutical science and gastroenterology, forging links between basic science and clinical outcomes. He leads a large and multi-disciplinary research group, and the goal of his work is to further the understanding of gastrointestinal physiology by fundamental research. So far, this knowledge has been translated into the design of new technologies and improved disease treatments, many of which are currently in late stage clinical trials.. Abdul is also the only non-North American scientist to receive the Young Investigator Award in Pharmaceutics and Pharmaceutical Technology from the American Association of Pharmaceutical Scientists (AAPS). Moreover, he is the founder and director of two spin-out companies, and serves on the scientific advisory boards of pharmaceutical companies, healthcare organisations and charitable bodies, including the Clinton Health Access Initiative (CHAI).. . Winner of the 2014 Royal Pharmaceutical Society Science Award announced. Professor Benjamin J. Whalley has been announced as winner of the 2014 Royal Pharmaceutical Society’s prestigious Science Award. The award will be presented at the APS PhamSci 2014 conference at the University of Hertfordshire, when Professor Whalley will deliver a plenary lecture on The therapeutic value of non-psychoactive components of cannabis in epilepsy: from lab to clinic.. The lecture will take place on Tuesday 9th September at 1335.. . . . The RPS Science Award has a long history with previous winners invariably going on to make significant contributions in the field of pharmaceutical science. The award is presented to a pharmaceutical scientist with no more than 10 years’ experience at post-doctoral level who has a proven record of independent research and published work that shows outstanding promise.. Professor Benjamin J. Whalley studies neuronal processes that underlie complex physiological functions, specifically neuronal hyperexcitability states and their consequential disorders (e.g. epilepsy, ataxia and dystonias). As a registered pharmacist (1992-present), Professor Whalley’s research in this area has primarily focused upon preclinical drug development in epilepsy. Here, he has primarily employed electrophysiological approaches with a variety of in vitro models of epileptiform activity and a number of in vivo rodent models of seizure and epilepsy.. He has used these approaches to examine the cellular and neuronal network mechanisms that underlie the effects of anti-epileptic drugs (AEDs) that are in clinical use or currently in clinical trials (e.g. levetiracetam (UCB Pharmaceuticals), carisbamate and topiramate (RW Johnson)). More recently, his work has examined the effects of several non-psychoactive components of marijuana (‘phytocannabinoids’) upon hyperexcitability states. Here, he has demonstrated that several of these phytocannabinoids exert significant anti-epileptic effects and, since 2008, has worked with GW Pharmaceuticals and Otsuka Pharmaceuticals to develop these drugs to the point of translation to human clinical trials. This work has yielded 4 international patents and, in 2013, initiation of Phase 1 human clinical trials for one drug (cannabidavarin) and Phase 2 human clinical trials for another (cannabidiol) in drug resistant, pediatric epilepsies. Early efficacy data from these trials has shown that cannabidiol has beneficial effects upon seizures in otherwise treatment-resistant paediatric epilepsy patients.. Prof. Whalley’s expertise in this area is further reflected in his role as an expert witness in criminal trials involving cannabis, his invited authorship of The American Herbal Pharmacopeia’s monograph on Cannabis and Epilepsy and recent appointment to the UK Advisory Council on the Misuse of Drugs. His work with non-psychoactive phytocannabinoids has also included work with colleagues which has revealed cannabinoid effects upon appetite and feeding behaviours, anti-ataxic mechanisms of action in the cerebellum and ongoing studies of the effect of these compounds in cachexic states.. A significant component of Prof. Whalley’s research has also been the development of experimental platforms which combine biological (e.g. neuronal cell culture, acute brain slices) and machine (e.g. robotic) systems to produce brain-machine interfaces (BMI) as tools for investigating the cellular correlates of complex CNS functions, including stem cell-based approaches. This research has thus far culminated in development of the first bioelectrically functional, 3D human neuronal network from stem cells, using biocompatible scaffolds; work featured in recent BBC science programming. This BMI research has formed part of presentations to the UK Cabinet Office and the US Senate, features in New Scientist, The Lancet, national broadsheets, national and international television and radio, an exhibit at the London Science Museum.. Both of the above research strands were chosen to act as two of the three Research Excellence Framework (REF) Impact Case Studies submitted by the Reading School of Pharmacy. Prof. Whalley has won ~£6M grant funding since taking up his first independent academic position in 2005 and his current grant funding supports a research group of 2 PDRAs and 9 PhD students. He has successfully supervised 13 PhD students to completion (100% success rate)..
Last chance to register for the Annual APS PHARMSCI 2014 conference
TUESDAY, 2 SEPTEMBER 2014
. . APS PHARMSCI 2014 CONFERENCE at the University of Hertfordshire de Havilland Campus, Hatfield from Monday 8th to Wednesday 10th September 2014.. http://www.ukpharmsci.org/default.asp. With only a few days to go to this year’s APS PharmSci 2014 Conference, is proving one not to be missed by anyone working in the pharmaceutical science sector. With over 500 delegates registered and a programme of plenary lectures and sessions that will have something to appeal to all pharmaceutical scientists.. The speaker for the first Plenary Session is Dr Linda Hakes, who is this year’s APS PharmSci 2014 Scientific Chair and she will talk on the theme of the conference – ‘Working together, for patients'. Delegates will then have a choice of 42 parallel sessions over the 3 days, with over 100 speakers and chairs, talking on areas of pharmaceutical sciences that is both cutting edge science and shows how pharmaceutical scientists are experts in the research, development and manufacture medicines and have a major role in the regulation of medicines and understanding their use in patients. There will be many opportunities to network with the speakers for discussions and questions.. Speakers will talk over the three days, on subjects ranging from Nanotechnology in Pharma: Past, Present and Future; Future benefits and current analytical challenges; Oral dissolving dosage forms: Current opportunities; Microbiology; Age-related Medicines; Pharmacognosy - Drugs from Natural Sources; Biomaterials; Biopharmaceuticals; Process validation and continuous process verification; Medicinal Chemistry; Parenteral Drug Development: The Challenges of Adapting to Changing Patient Needs; Targeting skin and mucous membranes; Challenges with biotherapeutic development; Material Sciences; Skin delivery at the interface of industry and academia, and Inhaled: New Technologies and Novel Therapeutics. A roundtable session will introduce the concept of a drug product Manufacturing Classification System (MCS) based on processing route and seek feedback from the wider pharmaceutical science community on the best way to apply it to practice. The conference also has sessions for New Scientists which will include presentations from established and emerging scientists, and the Student Association of the APS will present a session on networking and the use of social media to succeed. . Several plenary sessions will be delivered over the 3 days by the winners of awards, 2014 Royal Pharmaceutical Society Science Award, APS Invited lecture, and GSK Emerging Scientist Award 2014.. A Science Café looking at the Investment in new antibiotics or the supply of fresh water - which will save more lives? , will prove a good way to start your conference on the second day.. There is also an opportunity for SMEs to show case their technologies at 2 dedicated sessions.. There will also be opportunities to view the 325 posters that have been submitted over the 3 days and talk with the authors.. For further networking opportunities and to enjoy the social side of the conference there are events organised each day, on the Monday evening, what will prove to be a lively debate, The role of universities in open innovation research: academic entrepreneurship or industrial exploitation?’ and on the Tuesday evening the APS annual “Black Tie Dinner" at Knebworth House.. For more information on these sessions. please see our news blog section here:. http://www.apsgb.co.uk/blog2/default.asp. There is still time to register for the conference, for the full programme and registration see http://www.ukpharmsci.org/default.asp. .
The role of universities in open innovation research: academic entrepreneurship or industrial exploitation- You have your say
TUESDAY, 2 SEPTEMBER 2014
“Open innovation” describes a new paradigm for the management of industrial innovation in the 21st century, in which universities can work with external partners to both commercialise their internal innovations and to obtain a source of external innovations that can be commercialized. The term was coined by Henry Chesbrough, based on his research on the innovation practices of large multinational companies.. What are your thoughts on this way of working? Would you like to be part of what will prove to be a lively debate jointly organised by the APS, University of Hertfordshire and Stevenage Bioscience Catalyst on Monday 8th September 7pm at the APS Pharm Sci 2014. ?. The debate will be led by Dr Darragh Murnane, Associate Dean Enterprise, University of Hertfordshire. The debating panel consists of three prominent speakers Professor Bill Dawson representing Stevenage Bioscience Catalyst, Professor Marc Brown of UH/MedPharm Ltd and Professor Adrian Davis of Limeway Consultancy who each will deliver a statement speech followed by the panel discussion. Then it will be your chance to get involved and ask questions of the panel.. The event is free with an optional cost of £10 for a buffet and will take place at the De Havilland Club, De Havilland Campus, University of Hertfordshire.. For more information please click on the following link http://www.ukpharmsci.org/speakers2014/aps_conjunction.asp.
Follow us
 
Upcoming Events
MIBio 2014 - Stability of biopharmaceuticals- getting the chemistry right
30th September 2014
APS Board Meeting
14 - 15 October 2014
APS Industrial Insights 2015
16 - 17 April 2015
APS PharmSci 2015
7 - 9 September 2015
APS PharmSci 2016
5 - 7 September 2016
Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.

 

The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365
Email: info@apsgb.org

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.